This study is for people with HIV who have stable, low levels of the virus in their blood, referred to as "virologically suppressed" (HIV-1 RNA < 50 copies/mL). It aims to compare two treatment regimens: a new weekly pill made of islatravir and lenacapavir (ISL/LEN), versus the standard daily treatment, bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). The goal is to see if the weekly pill is as effective as the daily one over 48 weeks.
- Duration: The study lasts 48 weeks.
- Eligibility: You must have been on B/F/TAF for at least 6 months with stable virus levels. You cannot have had past treatment failures or certain infections like hepatitis B or active hepatitis C.
- Considerations: Participants will be monitored for safety and effectiveness of the new weekly regimen.
If you are eligible, participation involves regular health check-ups and following the study's guidelines on medication. It's important to discuss with your doctor if joining this study is right for you.
How understandable was the trial content above?
Hard to understand
Easy to understand